Established in 2003 by preeminent Japanese university researchers, REPROCELL quickly became the leading stem cell research company in Japan. Soon thereafter, REPROCELL products were employed by Professor Shinya Yamanaka during his pioneering research on iPSC technologies at Kyoto University. We were the first company to offer iPSC-derived human cardiomyocytes, hepatocytes, and neuronal cells for research applications and were listed on the Japan JASDAQ / Growth stock market in 2013.
In recent years, REPROCELL has expanded through a series of acquisitions. This expansion has created a workflow - including human tissue acquisition (BioServe®), RNA reprogramming (Stemgent®), 3D technologies (Reinnervate®), and drug discovery (Biopta®) - in addition to our core capabilities. These acquisitions have been consolidated to regional offices, and the names converted to daughter brands. In the stem cell and drug discovery “market- space”, no other company has such a broad combination of expertise that can be applied to drug discovery and regenerative medicine. To find out more about REPROCELL's capabilities, download our Corporate Capabilities Guide (PDF).
Over the last decade, REPROCELL has evolved its global infrastructure, corporate organization, and strategy. By leveraging our knowledge base of stem cell technologies, REPROCELL has planned a future that directly involves the pursuit of regenerative medicine market opportunities. This evolution has compelled us to restructure, modify, and define our future vision. If you are interested in finding out more, the REPROCELL Corporate Profile Guide (PDF) concisely explains our current organization and provides a guideline for corporate development and operations.
Find out more about the services and products we offer to better translate your discoveries into therapies.